Metastatic Gastric Cancer clinical trials

Explore recruiting metastatic gastric cancer clinical trials.

Recruiting metastatic gastric cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Gastric Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Watch-and-wait strategy to initiate Dostarlimab-based Immunotherapy in localized deficient mismatch repair (dMMR) and/or microsatellite instability high (MSI-H) oEso-gastric junction and gastric adenocarcinoma: A two cohort open-label GERCOR phase II study

France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC)

Austria, Germany, France, Spain, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Randomised Phase III Trial of First Line Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy Alone in Gastric Cancer Patients with Peritoneal Metastases

Italy, Sweden, Netherlands, Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metastatic gastric cancer: A randomized GERCOR phase II study (BIG)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin 18.2 (CLARITY-Gastric 01)

Germany, Poland, France, Italy, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Metastatic Gastric Cancer trials by city

Metastatic Gastric Cancer clinical trials

Recruiting metastatic gastric cancer studies right now

Intravital Microscopy in Human Solid Tumors

Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

HER-2 B Cell Peptide Vaccine

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors

IDOV-Immune for Advanced Solid Tumors

A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer